CR8224A - Polipepticos cristalinos del receptor 2 del factor de necrosis de tumor - Google Patents

Polipepticos cristalinos del receptor 2 del factor de necrosis de tumor

Info

Publication number
CR8224A
CR8224A CR8224A CR8224A CR8224A CR 8224 A CR8224 A CR 8224A CR 8224 A CR8224 A CR 8224A CR 8224 A CR8224 A CR 8224A CR 8224 A CR8224 A CR 8224A
Authority
CR
Costa Rica
Prior art keywords
crystal
polipeptices
necrosis factor
tumor necrosis
factor receptor
Prior art date
Application number
CR8224A
Other languages
English (en)
Inventor
Osslund Timothy
L Clogston Christi
Lee Crampton Shon
B Bass Randal
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CR8224A publication Critical patent/CR8224A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion suministra formas cristalinas de los polipeptidos TNFR2, que incluyen los polipeptidos TNFR2:Fc y el etanercept cristalino. Una modalidad de la invencion es un cristal de etanercept; en ciertas modalidades el cristal de etanercept esta en la forma de una barra, y /o tiene una longitud maxima de entre 0.5 milimetros y 1.5 milimetros de entre 0.05 milimetros y 0.3 milimetros.
CR8224A 2003-08-01 2006-02-01 Polipepticos cristalinos del receptor 2 del factor de necrosis de tumor CR8224A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49182703P 2003-08-01 2003-08-01

Publications (1)

Publication Number Publication Date
CR8224A true CR8224A (es) 2006-07-18

Family

ID=34115556

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8224A CR8224A (es) 2003-08-01 2006-02-01 Polipepticos cristalinos del receptor 2 del factor de necrosis de tumor

Country Status (18)

Country Link
US (1) US7276477B2 (es)
EP (1) EP1654281A1 (es)
JP (1) JP2007521315A (es)
KR (1) KR20070008501A (es)
CN (1) CN100509847C (es)
AU (1) AU2004262014B2 (es)
BR (1) BRPI0413197A (es)
CA (1) CA2533796A1 (es)
CR (1) CR8224A (es)
EC (1) ECSP066299A (es)
IL (1) IL173413A0 (es)
NO (1) NO20060128L (es)
NZ (1) NZ545221A (es)
RU (1) RU2006101216A (es)
SG (1) SG145712A1 (es)
TW (1) TWI291468B (es)
WO (1) WO2005012353A1 (es)
ZA (1) ZA200600909B (es)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549895B2 (en) * 2004-04-23 2017-01-24 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
US20060046960A1 (en) * 2004-09-02 2006-03-02 Mckay William F Controlled and directed local delivery of anti-inflammatory compositions
WO2006079176A1 (en) * 2005-01-28 2006-08-03 Apollo Life Sciences Limited Molecules and chimeric molecules thereof
CN1954882A (zh) * 2005-10-14 2007-05-02 李海 长效人重组可溶性肿瘤坏死因子α受体在制备防治肝衰竭药物中的用途
US20070105807A1 (en) * 2005-11-10 2007-05-10 Sazani Peter L Splice switch oligomers for TNF superfamily receptors and their use in treatment of disease
WO2007062337A2 (en) * 2005-11-18 2007-05-31 Astrazeneca Ab Crystalline forms
US8389510B2 (en) * 2005-11-18 2013-03-05 Astrazeneca Ab Crystalline forms
US20090069291A1 (en) * 2005-11-18 2009-03-12 Astrazeneca Ab Salt Forms
WO2007062339A2 (en) * 2005-11-18 2007-05-31 Astrazeneca Ab Liquid formulations
US20090215744A1 (en) * 2005-11-18 2009-08-27 Astrazeneca Ab Solid Formulations
WO2007100937A2 (en) * 2006-01-19 2007-09-07 The Regents Of The University Of Michigan System and method for spectroscopic photoacoustic tomography
WO2007102946A2 (en) * 2006-01-23 2007-09-13 Amgen Inc. Crystalline polypeptides
US20100034808A1 (en) * 2006-11-21 2010-02-11 Toru Nakazawa Compositions and methods for preserving cells of the eye
WO2008067438A2 (en) * 2006-11-29 2008-06-05 The Regents Of University Of Michigan System and method for photoacoustic guided diffuse optical imaging
US20110268749A1 (en) * 2007-07-31 2011-11-03 The Government of the US as Represented by the Secretary Department of Health and Human Services Treatment of cancer via targeting of il-13 receptor-alpha2
KR101666228B1 (ko) 2007-09-28 2016-10-13 인트렉손 코포레이션 생물치료학적 분자를 발현시키기 위한 치료학적 유전자-스위치 작제물 및 생물반응기, 및 이의 용도
SG10201402265YA (en) * 2008-02-07 2014-08-28 Amgen Inc Stabilized protein compositions
CN101591388A (zh) * 2008-05-30 2009-12-02 上海复旦张江生物医药股份有限公司 一种可溶性tnf受体突变体
EP2461679B1 (en) * 2009-07-28 2019-02-13 GE Healthcare Bio-Sciences Corp. Vaccine stabilizer
JP5854513B2 (ja) 2009-08-03 2016-02-09 インキューブ ラブズ， エルエルシー 腸管内でインクレチン生産を刺激するための嚥下可能カプセルおよび方法
MX2012004877A (es) 2009-10-26 2012-05-23 Prometheus Lab Inc Analisis para la deteccion de farmacos anti-tnf y autoanticuerpos.
US8722615B2 (en) * 2009-12-02 2014-05-13 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
US8759284B2 (en) 2009-12-24 2014-06-24 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
EP2568960B1 (en) * 2010-05-10 2018-06-06 Intas Pharmaceuticals Ltd. Liquid formulation of polypeptides containing an fc domain of an immunoglobulin
SG189391A1 (en) 2010-10-18 2013-05-31 Nestec Sa Methods for determining anti-drug antibody isotypes
US8809271B2 (en) 2010-12-23 2014-08-19 Rani Therapeutics, Llc Therapeutic agent preparations comprising liraglutide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8734429B2 (en) 2010-12-23 2014-05-27 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
US8980822B2 (en) 2010-12-23 2015-03-17 Rani Therapeutics, Llc Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9283179B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9629799B2 (en) 2010-12-23 2017-04-25 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9259386B2 (en) 2010-12-23 2016-02-16 Rani Therapeutics, Llc Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9861683B2 (en) 2010-12-23 2018-01-09 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402807B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8846040B2 (en) * 2010-12-23 2014-09-30 Rani Therapeutics, Llc Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9415004B2 (en) 2010-12-23 2016-08-16 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8969293B2 (en) 2010-12-23 2015-03-03 Rani Therapeutics, Llc Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402806B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10639272B2 (en) 2010-12-23 2020-05-05 Rani Therapeutics, Llc Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
US8809269B2 (en) 2010-12-23 2014-08-19 Rani Therapeutics, Llc Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9284367B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
EP2678030A4 (en) * 2011-02-25 2015-02-18 Merck Sharp & Dohme PREPARATION OF N- AND O-SIALYLATED TNFRII-FC FUSION PROTEINS IN YEAST
EP2699265B1 (en) * 2011-04-20 2019-10-16 Sandoz AG STABLE PHARMACEUTICAL LIQUID FORMULATIONS OF THE FUSION PROTEIN TNFR:Fc
UY34105A (es) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
US8883982B2 (en) 2011-06-08 2014-11-11 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
EP2726090B1 (en) * 2011-07-01 2020-01-01 Biogen MA Inc. Arginine - free tnfr : fc- fusion polypeptide compositions
AU2012278802B2 (en) 2011-07-06 2015-11-26 Société des Produits Nestlé S.A. Assays for detecting neutralizing autoantibodies to biologic therapy with TNF alpha
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
CN104011073B (zh) 2011-10-18 2017-08-25 科荣生生物科学公司 使用氨基酸稳定的依那西普制剂
EP2869816A4 (en) * 2012-07-09 2016-04-20 Coherus Biosciences Inc ETANERCEPT FORMULATIONS WITH CLEAR REDUCTION OF SUBVISIBLE PARTICLES
RS57013B1 (sr) 2012-09-11 2018-05-31 Coherus Biosciences Inc Korektno savijeni etanercept sa visokom čistoćom i odličnim prinosom
EP2916656B1 (en) 2012-11-09 2017-10-25 Cornell University Small molecule inhibitors of malt1
US9649383B2 (en) 2012-11-19 2017-05-16 Merck Sharp & Dohme Corp. Liquid formulations for TNFR:Fc fusion proteins
US9474803B2 (en) 2012-11-27 2016-10-25 Alteogen Inc. Composition for stabilizing fusion protein in which protein and FC domain are fused
BR112016011224A2 (pt) * 2013-11-29 2017-09-19 Ares Trading Sa Formulação líquida de uma proteína de fusão que compreende tnfr e região de fc
ES2733298T3 (es) * 2014-07-18 2019-11-28 Sandoz Ag Cuantificación de TNFR2:Fc plegado erróneamente
US9764122B2 (en) 2014-07-25 2017-09-19 Warsaw Orthopedic, Inc. Drug delivery device and methods having an occluding member
US9775978B2 (en) 2014-07-25 2017-10-03 Warsaw Orthopedic, Inc. Drug delivery device and methods having a retaining member
US9821059B2 (en) 2014-10-17 2017-11-21 Alteogen Inc. Composition for stabilizing protein and pharmaceutical formulation comprising the same
EP3017825A1 (en) * 2014-11-06 2016-05-11 Ludwig-Maximilians-Universität München An inhibitor of the RIPK1-dependent necrosis pathway and a pharmaceutical composition comprising the same
US20170258937A1 (en) * 2014-11-25 2017-09-14 Nanobiotix Pharmaceutical composition, preparation and uses thereof
JP2018500553A (ja) 2014-12-05 2018-01-11 ネステク ソシエテ アノニム 患者試料における生物製剤の検出のための間接的均一移動度シフトアッセイ
WO2016100232A1 (en) 2014-12-15 2016-06-23 The Regents Of The University Of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
US11384350B2 (en) 2014-12-15 2022-07-12 The Regents Of The University Of California Cytotoxic molecules responsive to intracellular ligands for selective T cell mediated killing
CA2970577A1 (en) 2014-12-22 2016-06-30 Ares Trading S.A. Liquid pharmaceutical composition
CN105636937B (zh) * 2015-01-27 2018-07-17 深圳华大生命科学研究院 用于保存生物样品的稳定剂
CA2978431C (en) * 2015-03-02 2023-10-24 180 Therapeutics Lp Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist
US10076650B2 (en) 2015-11-23 2018-09-18 Warsaw Orthopedic, Inc. Enhanced stylet for drug depot injector
US10549081B2 (en) 2016-06-23 2020-02-04 Warsaw Orthopedic, Inc. Drug delivery device and methods having a retaining member
KR20190057308A (ko) 2016-09-02 2019-05-28 더 리전츠 오브 더 유니버시티 오브 캘리포니아 인터류킨-6 수용체 알파-결합 단일 사슬 가변 단편을 포함하는 방법 및 조성물
CA3038894A1 (en) 2016-09-28 2018-04-05 Board Of Regents, The University Of Texas System Antibody and protein therapeutic formulations and uses thereof
WO2018080196A2 (ko) * 2016-10-28 2018-05-03 (주)셀트리온 안정한 약제학적 제제
US10434261B2 (en) 2016-11-08 2019-10-08 Warsaw Orthopedic, Inc. Drug pellet delivery system and method
EP3813791A2 (en) * 2018-06-26 2021-05-05 Lupin Limited Stable lyophilized dosage form of protein
MY207630A (en) 2018-07-03 2025-03-06 Fennec Pharmaceuticals Inc Formulations of anhydrous sodium thiosulfate
CN111408343B (zh) * 2019-01-08 2022-01-28 湖南农业大学 三维立体生物炭的制备方法及其在重金属吸附中的应用
CN110433172B (zh) * 2019-07-10 2022-04-08 郴州市第一人民医院 一种具有治疗非小细胞肺癌功效的药物及其用途
MX2023006998A (es) 2020-12-22 2023-06-26 Amgen Inc Metodo de cultivo celular.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945397A (en) * 1989-09-05 1999-08-31 Immunex Corporation Purified p75 (type II) tumor necrosis factor receptor polypeptides
CN1098064C (zh) * 1995-11-07 2003-01-08 普罗克特和甘保尔公司 改进耐久型化妆品的性能的组合物及方法
JP4731793B2 (ja) * 2000-12-28 2011-07-27 アルセア テクノロジーズ インコーポレイテッド 抗体全体またはそのフラグメントの結晶、ならびにこの結晶を作製および使用するための方法

Also Published As

Publication number Publication date
JP2007521315A (ja) 2007-08-02
HK1093749A1 (zh) 2007-03-09
ECSP066299A (es) 2006-07-28
US7276477B2 (en) 2007-10-02
NZ545221A (en) 2009-09-25
TWI291468B (en) 2007-12-21
SG145712A1 (en) 2008-09-29
AU2004262014A1 (en) 2005-02-10
ZA200600909B (en) 2007-05-30
BRPI0413197A (pt) 2006-10-03
RU2006101216A (ru) 2007-07-20
WO2005012353A1 (en) 2005-02-10
IL173413A0 (en) 2006-06-11
NO20060128L (no) 2006-04-06
KR20070008501A (ko) 2007-01-17
EP1654281A1 (en) 2006-05-10
TW200510453A (en) 2005-03-16
CA2533796A1 (en) 2005-02-10
AU2004262014B2 (en) 2010-06-17
US20050032183A1 (en) 2005-02-10
CN1829739A (zh) 2006-09-06
CN100509847C (zh) 2009-07-08

Similar Documents

Publication Publication Date Title
CR8224A (es) Polipepticos cristalinos del receptor 2 del factor de necrosis de tumor
DE602004026113D1 (de) Glp-1-verbindungen
DK1581300T3 (da) Væskeapplikator med mekanisme til brydning af flere ampuller
BR0314196A (pt) Inibidores de tgf-beta
ECSP045474A (es) 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de 5-hidroxitriptamina-6
PA8637301A1 (es) Derivados de amino-5, 5-difenilimidazolona para la inhibicion de la b-secretasa
CY1113721T1 (el) Πολυσταθης ανακλαστικη διαταξη υγρων κρυσταλλων
ECSP044935A (es) Inhibidores de la dipeptidil peptidasa beta-amino heterocíclica para el tratamiento o la prevención de la diabetes
CL2009001214A1 (es) Compuestos derivados de heterociclo, moduladores de serina proteasas composicion fa<rmacaeutica que los comprende; y su uso en el tratamiento de trastornos tromboembolicos
ECSP024382A (es) Inhibidores de proteasa de serina
CR7583A (es) Nueva sal formiato de o-desmetil venlafaxina
NO20061122L (no) 2-(Quinoksalin-5-ylsuflonylamino)-benzamid forbindelser som CCK2 modulatorer
CR7042A (es) Indanil aminas aciladas y su uso como farmacos
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
AR034231A1 (es) Composicion farmaceutica que contiene mosaprida y pancreatina
AR025691A1 (es) Uso de csaids en infecciones por rinovirus
EA200602221A1 (ru) Новое применение пептидных соединений для лечения боли при тригеминальной невралгии
UY29774A1 (es) Inhibidor de atm
ATE445402T1 (de) Neue verwendung von pde5-hemmern
ATE496892T1 (de) Tetrahydroisochinolinverbindungen zur behandlung von zns-erkrankungen
ATE409188T1 (de) Naphthyridinverbindungen
DE60323645D1 (de) Duschvorrichtung mit bräunungsvorrichtung
UY28344A1 (es) Nuevos compuestos
ATE363511T1 (de) Trennfilme
ATE407466T1 (de) Schleifringbürste und damit ausgestattete schleifringeinheit

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)